Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Share-based Compensation (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Share-based Compensation for 3 consecutive years, with $1.2 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Share-based Compensation fell 70.76% year-over-year to $1.2 million, compared with a TTM value of $4.1 million through Dec 2024, down 3.77%, and an annual FY2024 reading of $4.1 million, down 3.77% over the prior year.
  • Share-based Compensation was $1.2 million for Q4 2024 at Oramed Pharmaceuticals, up from $301000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $4.2 million in Q4 2023 and bottomed at -$2.0 million in Q3 2023.
  • Average Share-based Compensation over 3 years is $1.6 million, with a median of $1.6 million recorded in 2023.
  • The sharpest move saw Share-based Compensation crashed 165.05% in 2023, then soared 647.98% in 2024.
  • Year by year, Share-based Compensation stood at $2.5 million in 2022, then skyrocketed by 64.95% to $4.2 million in 2023, then plummeted by 70.76% to $1.2 million in 2024.
  • Business Quant data shows Share-based Compensation for ORMP at $1.2 million in Q4 2024, $301000.0 in Q3 2024, and $1.2 million in Q2 2024.